Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Individuals with neurological diseases are at increased risk of fractures within 180 days of admission to long-term care in Ontario.
[Two new oral disease modifying therapies in relapsing remitting multiple sclerosis].
Interferon-Beta: Neutralizing Antibodies, Binding Antibodies, Pharmacokinetics and Pharmacodynamics, and Clinical Outcomes.
Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.
Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses.
DRUG DELIVERY TO CNS: CHALLENGES AND OPPORTUNITIES WITH EMPHASIS ON BIOMATERIALS BASED DRUG DELIVERY STRATEGIES.
Local dynamic stability as a responsive index for the evaluation of rehabilitation effect on fall risk in patients with multiple sclerosis: a longitudinal study.
Which is the goal of cognitive rehabilitation in multiple sclerosis: the improvement of cognitive performance or the perception of cognitive deficits?
Age of the Donor Reduces the Ability of Human Adipose-Derived Stem Cells to Alleviate Symptoms in the Experimental Autoimmune Encephalomyelitis Mouse Model.
Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing-Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study.
Myelin architecture: zippering membranes tightly together.
Review of laquinimod and its therapeutic potential in multiple sclerosis.
Clinical neurophysiology of multiple sclerosis.
Effects of dextromethorphan on glial cell function: Proliferation, maturation, and protection from cytotoxic molecules.
Cortical N-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis.
Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation.
Children and adolescents adjustment to parental multiple sclerosis: a systematic review.
Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial.
Multiple sclerosis: Natalizumab to fingolimod-the washout whitewash.
The Incidence and Prevalence of Thyroid Disease Do Not Differ in the Multiple Sclerosis and General Populations: A Validation Study Using Administrative Data.
Positive or negative involvement of heat shock proteins in multiple sclerosis pathogenesis: an overview.
Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?
The analysis of semantic networks in multiple sclerosis identifies preferential damage of long-range connectivity.
B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway.
Multisystem involvement in neuromyelitis optica.

Pages